Evidence-Based Diabetes Management > December 2017
Evidence-Based Diabetes Management - December 2017
Evidence-Based Diabetes Management
“Sprint to Zero“: A Strategy to Address High Rates of Nontraumatic Amputations in Minority Communities
December 12, 2017 – Jeffrey Carr, MD, FACC, FSCAI
CMS can take steps to raise awareness, including a specific quality measure, to ensure that testing occurs prior to nontraumatic amputation.
Eldrin F. Lewis, MD, MPH, on Heart Failure's Place in Diabetes Drug Trials, and the Promise of SGLT2s in Prevention
December 13, 2017 – Mary Caffrey
The payment reform movement has changed the thinking about what can be done for patients with diabetes and heart failure, for the good of patients.
December 13, 2017 – Robert A. Gabbay, MD, PhD, FACP
From the Editor in Chief
December 14, 2017 – Thomas R. Graf, MD
A chief medical officer for a major payer outlines the challenges making sure that certain high-cost therapies are directed to the patients who need them.
December 18, 2017 – Andrew Smith
Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.
December 26, 2017 – Mary Caffrey
December 19, 2017 – Mary Caffrey
An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.
January 03, 2018 – AJMC Staff
January 08, 2018 – AJMC Staff